Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14481180 | 0.88 | CHRNA7 (0.45) | KDM4ECHRNA7ALDH1A1MAPTPOLB | |
| SCHEMBL8641 | 0.85 | KDM4E (0.40) | KDM4EALDH1A1PKMMAPTACHE | |
| SCHEMBL14481065 | 0.85 | KDM4E (0.40) | KDM4EALDH1A1PKMMAPTACHE | |
| SCHEMBL715924 | 0.84 | OPRK1 (0.41) | KDM4EALDH1A1PKMMAPTPOLB | |
| SCHEMBL14481792 | 0.83 | OPRK1 (0.39) | MEN1KMT2AOPRK1 | |
| SCHEMBL14481349 | 0.80 | MAPT (0.42) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL14480924 | 0.80 | OPRK1 (0.39) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2115242 | 0.80 | KDM4E (0.35) | KDM4EALDH1A1PKMMAPTACHE | |
| SCHEMBL2115241 | 0.80 | KDM4E (0.35) | KDM4EALDH1A1PKMMAPTACHE | |
| SCHEMBL714749 | 0.80 | OPRK1 (0.39) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653105-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2014-02-18 | — | — | US | disclosed |
| US-20130012517-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-01-10 | — | — | US | disclosed |
| EP-2499129-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011058108-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012517-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | PDXK, MAP2K2, PDPK1 | KDM4E 2666/4885CHRNA7 829/4885ALDH1A1 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.